U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

2-CHLOROPYRIDINE OXIDE

MORE DETAILS

1B7DYF9G1Z

Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)

SB-267268

MORE DETAILS

N7AXG87WLD

Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)

SB-273005

MORE DETAILS

  HG7MY8V9AA

Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Integrin alpha-V/beta-3
9
Conditions:
Rheumatoid arthritis
320
Postmenopausal osteoporosis
59
SB-273005 is one in a series of orally active nonpeptide vitronectin αvβ3 inhibitors. SB-273005 had been in phase I clinical trials by GlaxoSmithKline for the treatment of postmenopausal osteoporosis and rheumatoid arthritis (RA). However, this research has been discontinued.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966